No licensed hantavirus vaccine is available outside limited use of Hantavax in South Korea, with multiple candidates—including mRNA platforms from Moderna and Korea University and DNA vaccines—remaining in preclinical or early Phase 1/2 stages as of mid-2026. Recent outbreaks have spurred attention and funding for orthohantavirus countermeasures, yet no Phase 3 efficacy trials are underway, reflecting the virus's low incidence, challenges in field testing, and typical multi-year regulatory timelines for safety and immunogenicity data. Trader consensus at 94.5% for no approval this year aligns with these constraints. Accelerated emergency pathways or unexpected trial breakthroughs could shift timelines, though current model consensus and development pace make such outcomes improbable before year-end.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% সম্ভাবনা
$129,738 Vol.
$129,738 Vol.
Dec 30, 2026
6% সম্ভাবনা
$129,738 Vol.
$129,738 Vol.
Dec 30, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine is available outside limited use of Hantavax in South Korea, with multiple candidates—including mRNA platforms from Moderna and Korea University and DNA vaccines—remaining in preclinical or early Phase 1/2 stages as of mid-2026. Recent outbreaks have spurred attention and funding for orthohantavirus countermeasures, yet no Phase 3 efficacy trials are underway, reflecting the virus's low incidence, challenges in field testing, and typical multi-year regulatory timelines for safety and immunogenicity data. Trader consensus at 94.5% for no approval this year aligns with these constraints. Accelerated emergency pathways or unexpected trial breakthroughs could shift timelines, though current model consensus and development pace make such outcomes improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 4, 2026, 10:39 AM ET
ভলিউম
$129,738শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine is available outside limited use of Hantavax in South Korea, with multiple candidates—including mRNA platforms from Moderna and Korea University and DNA vaccines—remaining in preclinical or early Phase 1/2 stages as of mid-2026. Recent outbreaks have spurred attention and funding for orthohantavirus countermeasures, yet no Phase 3 efficacy trials are underway, reflecting the virus's low incidence, challenges in field testing, and typical multi-year regulatory timelines for safety and immunogenicity data. Trader consensus at 94.5% for no approval this year aligns with these constraints. Accelerated emergency pathways or unexpected trial breakthroughs could shift timelines, though current model consensus and development pace make such outcomes improbable before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ভলিউম
$129,738শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine is available outside limited use of Hantavax in South Korea, with multiple candidates—including mRNA platforms from Moderna and Korea University and DNA vaccines—remaining in preclinical or early Phase 1/2 stages as of mid-2026. Recent outbreaks have spurred attention and funding for orthohantavirus countermeasures, yet no Phase 3 efficacy trials are underway, reflecting the virus's low incidence, challenges in field testing, and typical multi-year regulatory timelines for safety and immunogenicity data. Trader consensus at 94.5% for no approval this year aligns with these constraints. Accelerated emergency pathways or unexpected trial breakthroughs could shift timelines, though current model consensus and development pace make such outcomes improbable before year-end.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা